Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese
Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.